On paper, the Swedish life sciences sector is thriving. The sector had a turnover of 508 billion kronor in 2023 and accounts for almost 10 per cent of Sweden’s exports of manufactured goods, making it the country’s second-largest export sector¹. But the figures mask a different reality. For most companies, day-to-day life revolves around finding the money for the next step, and that hunt is taking up an increasing proportion of their time and resources.
Two new reports from SwedenBIO, the Life Science Barometer 2026¹ and the Pipeline Report 2026², show both the scale of the potential and how much of it risks being held back by funding issues.
A pipeline on a par with big pharma, driven by small companies
According to the Pipeline Report, 152 Swedish companies are collectively driving 518 drug development projects². In the preclinical stage, Sweden has more than twice as many assets as pharmaceutical giants such as Roche and AstraZeneca².
This is achieved with limited resources. The entire pipeline is driven by 3,663 employees, and 73 per cent of the companies have fewer than ten employees². An equal proportion, 73 per cent, have an annual turnover of less than 10 million kronor². It is an industry brimming with ideas but with slim margins.
The hunt for funding requires ever more resources
SwedenBIO asked 203 life science leaders what they would like decision-makers to prioritise. Funding came top with 101 mentions, with calls for stronger funding structures, more early-stage capital and long-term stability¹. At the same time, companies are planning to allocate more of their resources to fundraising. On average, they expect to allocate 14 per cent of their resources to funding in the short term and 18 per cent in the longer term, up from 10 per cent and 13 per cent respectively the previous year¹.
Public funding is crucial for younger companies. Among the companies that took part in the survey, 31 per cent stated that they had received government grants, most of them being younger companies¹.
The consequences are evident in the pipeline. The report highlights persistent difficulties in taking projects from Phase II to Phase III and attributes this largely to insufficient funding². Since 2022, 17 companies have gone into administration or been wound up².
Research is carried out here, and companies want to recruit
Despite the challenging capital climate, research remains closely linked to Sweden. Ongoing research projects are the most common value-creating asset for companies in the domestic market. 55 per cent of respondents have research projects that create value in Sweden¹.
Confidence in the future is also strong. 58 per cent of the companies plan to increase their workforce in 2026. Only seven companies, 4 per cent, expect to reduce their workforce¹. This makes payroll costs for R&D staff one of the largest and most important items to optimise.
The R&D tax credit: capital already within the business
This is an opportunity that many companies do not fully utilise. The Swedish R&D tax credit reduces employer’s contributions and the general payroll tax for staff working in research and development. The reduction amounts to 20 per cent of the contribution base, which corresponds to almost two-thirds of the employer’s social security contributions for these employees. The ceiling is 3 million kronor per month per group. The deduction applies regardless of whether the company is making a profit or not, which makes it particularly valuable for companies that do not yet have any revenue.
For a company planning to hire more researchers, the savings could fund an additional post, extend the runway by a couple of months, or prevent a project from being put on hold whilst awaiting the next round of funding. Yet many companies miss out on all or part of the deduction. This is rarely because the research is lacking. It is because the documentation and internal procedures are inadequate when the Swedish Tax Agency reviews the application.
How Leyton can help
Leyton specialises in helping pharmaceutical and biotechnology companies realise the full value of their R&D investments. We know that time is the scarcest resource in a small company, particularly when a growing proportion is already taken up by fundraising. That is why we take care of the process, so that your researchers can focus on their research.
Specifically, we help you with the following:
- Identifying what qualifies. We review your projects, from the early discovery phase and pre-clinical research through to clinical trials and process development. We identify which activities and which employees qualify for the tax relief, including those that are easily overlooked.
- Producing robust documentation. We produce technical descriptions, time sheets and cost documentation that meet the Swedish Tax Agency’s requirements. We also help you implement procedures to ensure that documentation is kept up to date on an ongoing basis and does not need to be reconstructed retrospectively.
- Free up time for your core business. We handle the administrative work, so that your key personnel do not have to spend hours on regulations and forms.
- Support during audits. We present your case clearly and convincingly and support you in your dialogue with the Swedish Tax Agency should any queries or audits arise.
- Find the right grants. Many start-ups rely on grants. Through our grant scouting service, we help you identify and apply for the funding opportunities that suit your projects, so that less time is spent on the application process.
Whether you are an academic spin-off in the pre-clinical phase or an established company moving into clinical trials, Leyton helps you transform administratively burdensome processes into capital that can flow back into your research.
Summary
The Swedish life sciences sector has a large pipeline relative to its size, but a growing proportion of companies’ resources is being spent on the hunt for funding. Between funding rounds, the R&D tax credit represents capital that is already within the business, available regardless of whether the company is profitable or not.
The most important thing is to identify the right staff and document the work so that it stands up to scrutiny. The companies that get this right are best equipped to put more capital to work in their research.
References
- SwedenBIO. (2026). Life Science Barometer 2026. https://swedenbio.se/wp-content/uploads/2026/01/the-life-science-barometer-2026-hires.pdf
- SwedenBIO. (2025). The Swedish Drug Discovery and Development Pipeline 2026. https://swedenbio.se/wp-content/uploads/2025/10/lowres-the-swedish-drug-discovery-and-development-pipeline-2026.pdf